News
RNA
11.76
+1.82%
0.21
Weekly Report: what happened at RNA last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at RNA last week (0525-0529)?
Weekly Report · 06/01 10:47
Weekly Report: what happened at RNA last week (0518-0522)?
Weekly Report · 05/25 10:51
Weekly Report: what happened at RNA last week (0511-0515)?
Weekly Report · 05/18 10:51
Avidity Biosciences Initiated at Outperform by Leerink Partners
Dow Jones · 05/15 17:43
Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners
Dow Jones · 05/15 17:43
Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform
TipRanks · 05/15 16:48
Atrium Therapeutics, Inc. reports Q1 results
Seeking Alpha · 05/15 13:31
Atrium Therapeutics initiated with an Outperform at Leerink
TipRanks · 05/15 10:21
ATRIUM THERAPEUTICS INC <RNA.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $25
Reuters · 05/15 10:07
Atrium Therapeutics Q1 collaboration revenue surges after spin-off
Reuters · 05/14 20:50
*Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA
Dow Jones · 05/14 20:43
*Atrium Therapeutics 1Q Rev $19.6M >RNA
Dow Jones · 05/14 20:43
*Atrium Therapeutics 1Q Loss/Shr 97c >RNA
Dow Jones · 05/14 20:40
*Atrium Therapeutics 1Q Loss $16.6M >RNA
Dow Jones · 05/14 20:40
Trump Trade: U.S. plans AI security order without required model tests
TipRanks · 05/11 19:29
Trump approves plan to fire FDA head Marty Makary, CBS reports
TipRanks · 05/11 17:54
Weekly Report: what happened at RNA last week (0504-0508)?
Weekly Report · 05/11 10:48
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 05/08 19:05
Weekly Report: what happened at RNA last week (0427-0501)?
Weekly Report · 05/04 10:43
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Atrium Therapeutics, Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.